With short half-lives and fragmented regulations across borders, there’s no margin for error with radiopharmaceutical logistics. We spoke to World Courier’s Marco Hogenboom to discuss the critical challenges for this rapidly growing market and why World Courier’s fully in-house, end-to-end logistics model is a key benefit for radiopharma sponsors.
May 29, 2026
Radiopharmaceutical therapies are rapidly becoming mainstream in oncology. Credit via Shutterstock
Radiopharmaceutical therapies are moving from niche innovation to a mainstream oncology option. For supply chains built around stable, mass-produced medicines, radiopharma introduces a new set of constraints. These include short half-lives, strict temperature control, and overlapping pharmaceutical and radiation-safety regulations that can vary considerably by country.
Radiopharmaceuticals: precise targeting of cancer cells
